Stiles Financial Services’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$264K Sell
1,729
-408
-19% -$62.5K 0.08% 155
2025
Q4
$295K Sell
2,137
-576
-21% -$75.4K 0.09% 150
2025
Q3
$348K Sell
2,713
-534
-16% -$65.2K 0.11% 140
2025
Q2
$393K Buy
3,247
+51
+2% +$5.75K 0.14% 126
2025
Q1
$357K Sell
3,196
-53
-2% -$5.64K 0.14% 126
2024
Q4
$316K Hold
3,249
0.11% 142
2024
Q3
$374K Hold
3,249
0.13% 133
2024
Q2
$346K Buy
3,249
+46
+1% +$4.62K 0.13% 132
2024
Q1
$310K Buy
3,203
+500
+18% +$51.3K 0.12% 134
2023
Q4
$273K Sell
2,703
-303
-10% -$29.2K 0.12% 145
2023
Q3
$306K Hold
3,006
0.16% 132
2023
Q2
$303K Buy
3,006
+45
+2% +$4.5K 0.15% 142
2023
Q1
$272K Buy
2,961
+50
+2% +$4.37K 0.15% 148
2022
Q4
$264K Hold
2,911
0.15% 148
2022
Q3
$221K Buy
2,911
+230
+9% +$19.1K 0.13% 149
2022
Q2
$227K Sell
2,681
-19
-0.7% -$1.67K 0.14% 147
2022
Q1
$237K Buy
2,700
+93
+4% +$8.05K 0.12% 157
2021
Q4
$228K Buy
+2,607
New +$216K 0.11% 161

Other funds holding NVS

Stiles Financial Services's NVS Position: Q1 2026 in Review

Stiles Financial Services reduced its Novartis (NVS) stake by 19% in Q1 2026, selling an estimated $62.5K and leaving 1,729 shares worth $264K. The position accounts for 0.08% of the portfolio, ranked #155.

Stiles Financial Services first reported a position in NVS in Q4 2021 and has held it in 18 quarters since. The position peaked at $393K in Q2 2025. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Stiles Financial Services held 1,729 shares of Novartis worth $264K as of Q1 2026.
  • Stiles Financial Services sold 408 Novartis shares in Q1 2026, an estimated $62.5K.
  • Novartis made up 0.08% of Stiles Financial Services's portfolio in Q1 2026, its #155 holding.
  • Stiles Financial Services first reported a position in Novartis in Q4 2021 and has held it in 18 quarters since.
  • Stiles Financial Services's Novartis position peaked at $393K in Q2 2025.
  • 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Stiles Financial Services's 13F filing for Q1 2026, filed 30 Apr 2026.